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Abstract 
Over the last 5 years, there has been a dramatic increase in the use of extracorporeal membrane oxygenation (ECMO) 
in adult patients with severe respiratory or cardiac failure. This contrasts to the use of the technology in neonatal and 
paediatric intensive care units, where it has been regarded as a standard of care for a number of conditions for over 
25 years. Many innovations in ECMO circuitry or clinical management evolve first in one particular discipline and it 
may be helpful for individual clinicians to keep abreast of developments in ECMO across the entire age range, from 
neonatology to older adults. This review addresses nine concepts in ECMO that are better studied or established in 
paediatric medicine and considers their application in adult patients.
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Human nature will not change. In any future great 
national trial, compared with the men of this, we shall 
have as weak and as strong, as silly and as wise, as bad 
and as good. Let us therefore study the incidents in this 
as philosophy to learn wisdom from and none of them as 
wrongs to be avenged. Abraham Lincoln, 1865
Background
Patients started being treated with extracorporeal mem-
brane oxygenation (ECMO) in the 1970s. Initial results 
were encouraging but associated with many complica-
tions. The publication of the first randomized control trial 
(RCT) of ECMO for acute respiratory distress syndrome 
(ARDS) in adults by Zapol et  al. [1] showed no benefit 
and channelled efforts to improve the poor outcome for 
ARDS in other directions. However, Robert Bartlett from 
the University of Michigan decided to continue using 
ECMO in newborn infants with severe respiratory failure 
who could potentially recover more quickly than adults. 
This experience was quickly extended to older children 
and, in 1989, led to the establishment of the Extracor-
poreal Life Support Organization (ELSO) as a means of 
propagating knowledge about ECMO. Improved tech-
nology, equipment and understanding of patient and 
circuit pathophysiology led to a rapid increase in the use 
of ECMO for children. The use of ECMO for respira-
tory failure in adults continued in some centres during 
the 1990s but increased rapidly in the early 2000s and 
is now considered by many to be a standard therapy in 
many different clinical situations. The cumulative use 
of ECMO in patients is recorded by ELSO and reported 
biannually (Table  1). Over the last five years, there has 
been a dramatic increase in the use of ECMO in adults 
with respiratory or cardiac failure (Table 2). This explo-
sion in the use of ECMO in adults is often attributed to 
the 2009 influenza A(H1N1) pandemic, but has also been 
due to ever-expanding indications in adult cardiac sup-
port, including post-cardiotomy shock, myocarditis, and 
as a bridge to ventricular assist device or thoracic organ 
transplantation. In 2012, more cases of cardiac ECMO 
were reported to ELSO in adults than in children. In 
2013, the adult population similarly overtook the annual 
volume of paediatric and neonatal ECMO for respiratory 
indications.  
Many innovations in ECMO circuitry or clinical manage-
ment evolve first in one particular discipline. For example, 
the first use of dual-lumen ECMO catheters, the first rigor-
ous randomized controlled trial showing benefit to ECMO, 
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and the most extensive long-term outcome studies were all 
performed in neonatal patients. We believe that it is help-
ful for individual clinicians to keep abreast of developments 
in ECMO across the entire age range, from neonatology to 
older adults. This review addresses nine concepts in ECMO 
that are better studied or established in paediatric medicine 
and considers their application in adult patients.
Review
ECMO is not proven, but it works
There are a number of excellent recent reviews that sum-
marize the current clinical use of ECMO in critically ill 
adults with cardiopulmonary disease [2, 3] and also the 
evidence for either venoarterial [4] or venovenous ECMO 
[5, 6] in adults with primary cardiovascular or respira-
tory failure. It is interesting to consider that in an era of 
evidenced-based medicine and randomized controlled 
trials in critical care medicine, there are no studies that 
unequivocally prove the benefit of ECMO in adult 
patients. There are numerous studies that present out-
comes of patients in many different ways, but all of these 
are designed to encourage the use of ECMO for cardiac 
and/or pulmonary failure. These methods of data presen-
tation include:
1. A case series of patients with a particular problem 
who had good survival. These reports may suffer 
from publication bias.
2. A cohort compared to historical controls. These 
studies are usually positive because the newer treat-
ments are better than the old ones.
3. A cohort compared to matched case controls or pro-
pensity analysis. This can be a useful attempt to eval-
uate efficacy for complex clinical situations in terms 
of severity of illness, disease and multiple complex 
treatments.
4. A cohort compared to the ELSO database. This will 
favour the cohort because the ELSO database is pre-
sented cumulatively over 26 years, has many inexpe-
rienced centres with the initial “learning curve” prob-
lems and includes complications of both ECMO and 
disease.
5. Finally, there are three RCTs [1, 7, 8] in adult respira-
tory failure. The outcomes have been interpreted in 
different ways, depending on the view of those in 
favour or opposed to ECMO (Table 3).
There have been many cohort studies published in new-
born infants and children with respiratory or circulatory 
failure similar to the adult literature. Similarly, there have 
also been three RCTs published in children with respira-
tory failure (Table 4). Each one of these six RCTs has been 
subjected to criticisms of their methodology, such as 
problems with randomization, using outdated cannula-
tion and ventilation strategies, and failure to adequately 
standardize treatment in the control arms. The last criti-
cism was levelled at the most recent RCT in adult patients, 
the CESAR study [8], where patients in the control arm 
remained at their initial hospital and received whatever 
unstandardized care was provided to them, while those in 
the treatment arm were transported to a very experienced 
ECMO centre where the majority, not but all, received 
ECMO. Similar criticisms had been directed at the first 
successful RCT of ECMO in neonatal respiratory failure, 
conducted in the UK over a decade before [9]. It is inter-
esting to reflect on what level of proof needs to be demon-
strated in order to accept a new form of treatment or life 
support. In general, clinicians who are experienced with 
ECMO believe that its efficacy is self-evident and those 
Table 1 ELSO registry report: international summary (July 
2015)
ELSO extracorporeal life support organization, ECLS extracorporeal life support, 





Survived to DC or transfer 
(%)
Neonatal
Respiratory 28,217 23,791 84 20,978 74
Cardiac 6046 3750 62 2497 41
ECPR 1188 766 64 489 41
Paediatric
Respiratory 6929 4579 66 3979 57
Cardiac 7668 5084 66 3878 51
ECPR 2583 1432 55 1070 41
Adult
Respiratory 7922 5209 66 4576 58
Cardiac 6522 3661 56 2708 42
ECPR 1985 791 40 589 30
TOTAL 69,114 49,063 71 40,764 59
Table 2 ELSO data on  annual ECMO use 2010–2014 (July 
2015)
2010 2011 2012 2013 2014
Respiratory
Neonatal 884 847 850 779 850
Paediatric 379 411 472 491 470
Adult 529 666 949 1423 1779
Cardiac (patient age)
0–30 days 309 393 416 454 433
30 days–1 year 241 273 263 290 314
1–16 years 170 221 237 228 261
Over 16 years 423 597 1026 1235 1494
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who argue that there is insufficient evidence for it often 
have minimal experience with it. There is now more evi-
dence supporting the use of ECMO for certain conditions 
than for many other forms of life support. Where are the 
RCTs of mechanical ventilation versus normobaric oxy-
gen in ARDS, or inotropes versus placebo in septic shock?
The view of most neonatal and paediatric intensivists 
is that ECMO is a standard therapy that is part of clinical 
practice guidelines for critically ill children with diverse 
causes of cardiopulmonary failure. In a detailed review of 
recent evidence from 2002 to 2012 on the use of ECMO 
[10], the authors concluded, Despite a large number of 
published studies there remains a paucity of high-quality 
clinical trials. The available data support the continued 
use of ECMO for respiratory failure refractory to conven-
tional therapy for neonatal and pediatric patients with-
out significant comorbidities. Further research is needed 
to better quantify the benefit of ECMO and the utility 
of many therapies applied to ECMO patients. Another 
review [11] concluded that continued examination of the 
criteria and circumstances where extracorporeal life sup-
port is applied as well as outcomes which include mortal-
ity, cost effectiveness and quality of life are needed areas 
of continued research. In addition to these goals, further 
research should focus on the optimal timing of ECMO 
initiation, including examining the consequences of these 
decisions with detailed functional outcome studies.
The systems that provide ECMO vary: all are valid and all 
have their problems
The establishment of an ECMO programme will often 
have a key individual who becomes the main proponent or 
champion for the use of the technology. While most pae-
diatric programmes developed with a combination of neo-
natal physicians and general surgeons, some programmes 
developed from paediatric intensive care clinicians or car-
diothoracic surgeons. This has led to different systems of 
care for patients, different clinical care protocols, equip-
ment and cannulation techniques that vary dramatically 
across the world [12]. Peripheral cannulation may be per-
cutaneous or surgical and removal of these cannulas may 
or may not involve surgery, with or without vascular recon-
struction. Femoro-femoral cannulation has substantial risks 
of limb ischaemia, compartment syndrome and venous 
obstruction in children and adults, and much debate occurs 
about the best method of cannulation [13–18]. The choice 
of peripheral or central (transthoracic) cannulation also 
varies dramatically, even when cardiac surgeons perform 
Table 3 Randomized controlled trials in adult ECMO
CMV conventional mechanical ventilation, ECMO extracorporeal membrane oxygenation, VV venovenous, CESAR conventional ventilator support versus extracorporeal 







Pro-ECMO Anti-ECMO Today’s perspective
Zapol et al. [1] 4/48 (8 %) 4/42 (10 %) Change needed? Different 
patients with different 
diseases
Does not work VV not used, ECMO duration 
arbitrarily limited to 5 days, 
ECMO started very late
Morris et al. [7] 8/19 (42 %) 7/21 (33 %) 2/3 death due to bleeding, 
learning curve
Does not work, protocols  
are better
Small study, outdated ECMO 
technology, training is 
important
Peek et al. [8] 41/87 (47 %) 57/90 (63 %) ECMO works Only 68 % received ECMO Intention to treat analysis,
ECMO in care plan prob-
ably beneficial but still 
unproven
Table 4 Randomized controlled trials in neonatal and paediatric ECMO
CMV conventional mechanical ventilation, ECMO extracorporeal membrane oxygenation, UK United Kingdom





Bartlett et al. [52] 0/1 (0 %) 11/11 (100 %) It works, novel study 
design to minimize 
death rate
Amazement that the study 
was approved by the  
review board
Play the winner, possible 
bias, small numbers
O’Rourke et al. [53] 6/10 (60 %) 28/29 (97 %) It works It might work but is  
unproven
Small numbers
UK neonatal study [9] 38/92 (41 %) 63/93 (68 %) It works No standardized protocol 
for treatment of control 
patients
Suggestive of benefit but 
some methodological 
problems
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the procedure. An example of this is at the Royal Chil-
dren’s Hospital, Melbourne, Australia, where the majority 
of children who receive ECMO after cardiac surgery do so 
via central cannulation, while at East Midlands Congeni-
tal Heart Centre, Glenfield Hospital, Leicester, it is more 
common to cannulate through a jugular-carotid approach 
(G Peek, personal communication). There are greater risks 
of mediastinitis and reoperation for bleeding with central 
cannulation, whereas jugular-carotid cannulation is asso-
ciated with a higher risk of neurological injury [19]. Simi-
larly, there is a trend in some international centres caring 
for adult patients to move away from femoral cannulation 
and use more axillary arterial cannulation, which mitigates 
the risks of leg ischaemia and differential cyanosis, and 
facilitates extubation and ambulation on ECMO. The major 
downside to this approach is that it prolongs the time 
taken to cannulate and is not suitable during cardiac arrest. 
Ongoing reappraisal of the quality and methods of institu-
tional care is important as new evidence becomes available.
Configuration of cannulation should be physiologically 
based and may change over time
While each programme will have their method of cannula-
tion and their preferred configuration whether for VV [5] 
or VA ECMO [20], these should have a sound physiologi-
cal basis. An additional consideration in younger children 
relates to the size and development of the vasculature. 
ECMO cannulas in children occupy a greater proportion 
of the vessel cross-sectional area when compared to adults 
and, in infants, the femoral vessels are relatively hypoplas-
tic, making cannulation technically difficult or practically 
impossible. This limits the number of possible cannulation 
sites and drove researchers to develop the first dual-lumen 
VV ECMO catheters for use in the internal jugular vein. As 
children begin to walk and develop their leg muscles, the 
vessels grow and become easier to cannulate. Moreover, 
during the course of an ECMO run, new clinical situations 
with changing pathophysiology may necessitate an addi-
tional or complete change of cannulas. In children, this is 
often conversion of VA to VV in pneumonia, once circula-
tory collapse has resolved over the first 3 days, or the need 
for left atrial decompression in left heart failure [21]. In 
adults, these include the change from a standard VV con-
figuration to a VV-V, i.e. an extra drainage cannula, which 
will improve patient oxygen saturation or to V-VA, i.e. an 
extra arterial return catheter to augment circulatory func-
tion, which can be important in supporting the right ventri-
cle during prolonged respiratory failure.
Indications for ECMO are dynamic and change accordingly, 
albeit at different rates in different parts of the world
When ECMO started in children, the presence of active 
bacterial infection was considered a contraindication but 
some clinicians used ECMO for refractory septic shock 
regardless, and successful outcomes were first reported 
in the early 1990s [22]. Clinical practice guidelines and 
College recommendations in children with septic shock 
have included ECMO since 2002 [23]. The use of ECMO 
in adults with septic shock is now occurring in some cen-
tres [24, 25]. Likewise, ECMO was not recommended in 
children with leukaemia and immunosuppression until a 
review of the ELSO experience [26] and an accompany-
ing editorial [27] demonstrated good patient outcomes. 
Since then, many children with leukaemia and solid 
tumours are considered for ECMO. In both children and 
adults, ECMO is often used to support cardiopulmonary 
function for early graft failure after heart or lung trans-
plantation, with good results [28, 29].
As indications for initiating ECMO change, clinical 
management [2–6, 10–12] will also have to change. For 
example, if ECMO is used after cardiac surgery, bleeding 
will be more likely than if ECMO is not used. Younger 
children have immature coagulation systems, such as 
lower concentrations of antithrombin, and a greater pro-
pensity towards intracranial haemorrhage because of 
their fragile germinal matrices. They are thus more vul-
nerable to miscalculations in anticoagulation and blood 
product management. Clinicians change their practice 
to intensify monitoring of such values as anti-Xa and 
antithrombin levels. Similarly, adults after cardiopulmo-
nary bypass have a greater risk of bleeding complications, 
not just because of recent surgery, but also because of the 
formation of antithrombin-heparin complexes, platelet 
dysfunction and release of endogenous glycosaminogly-
cans induced by the bypass circuit [30]. If ECMO is used 
in patients with sepsis and disordered coagulation, then 
anticoagulation will become more difficult and circuit 
thrombosis and patient haemorrhage is more likely.
Goals of therapy are vital in effecting patient management 
and reducing complications
The principal goal of therapy with ECMO is to maximize 
quality of life and achieve patient survival with minimal 
complications. Targeting physiological goals may alter 
this. For example, a five-year-old has fulminant septic 
shock with refractory hypotension and progressive aci-
dosis. ECMO is commenced. What blood flow should 
the patient receive from the ECMO circuit? If 120  mls/
kg/min is chosen then this is achievable with peripheral 
cannulation; but if the goal of therapy is 150–200 mls/kg/
min then sternotomy and central cannulation with large 
cannula are needed. 120 ml/kg/min may be insufficient 
in some children with distributive shock; thus, peripheral 
cannulation may expose the child to the risks of ECMO 
without the benefits. This may be the reason for the poor 
outcomes seen in some studies of ECMO for adult septic 
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shock [24, 25]. Conversely, central ECMO may more eas-
ily achieve physiological goals but requires a dedicated 
cardiac surgical team and carries a greater risk of iatro-
genic bleeding and infection.
Another example is a 20-year-old with severe pneu-
monia and single organ failure on VV ECMO and with 
SaO2 80 %. All attempts to improve saturation fail. Some 
ECMO programmes would (in the presence of adequate 
haemoglobin, cardiac function and adequate perfusion) 
accept this, while others would insert an extra venous 
catheter to increase SaO2 to 90 %. Paediatric ECMO cli-
nicians have long experience managing children with 
cyanotic congenital heart disease and may be prepared 
to accept lower systemic oxygen saturations providing 
the arterial-venous oxygen difference, arterial lactate 
and organ function parameters are acceptable. There are 
many other less dramatic differences in how patients are 
managed on ECMO due to the many different therapeu-
tic goals such as fluid balance, blood pressure, nutrition, 
sedation and the team’s willingness to manage the patient 
with or without an endotracheal tube. Perhaps the most 
variation occurs in anticoagulation protocols of patients 
on ECMO because of differences in both monitoring and 
therapeutic goals.
Large, committed ECMO programmes have better 
outcomes
Large congenital cardiac surgical centres use ECMO for 
routine mechanical circulatory support for low cardiac 
output after surgery. However, outcomes are better if 
there is an in-house surgeon capable of rapid cannula-
tion [31] or if the ECMO is used early rather than delayed 
[32]. Not surprisingly, centres of excellence with large 
volumes have better patient results than centres with 
small volume of patients receiving ECMO [33, 34]. This 
effect appears particularly prominent for cardiac disease 
[33].
Outcome assessment is essential
Knowledge of patient outcome is an essential part of crit-
ical care. This is especially relevant to ECMO. However, 
what appears as a simple question, “what is my patient’s 
outcome?” actually requires a very complex answer [35]. 
What outcome should we choose and when should we 
assess it? Patient survival is the easiest to assess but at dis-
charge from ICU, discharge from hospital or some fixed 
time point after admission (e.g. 30 days) or 6–12 months 
after discharge? If we do a functional assessment, do we 
examine disease-specific or global-assessment outcomes? 
Do we use quality-of-life tools (generic or specific) and if 
so, from whose perspective? Do we do a telephone inter-
view or examine the patient? Long-term outcomes have 
been part of neonatal and paediatric care for many years 
and outcomes are well known [36, 37]. Unfortunately, 
they reflect treatment protocols that no longer exist and 
have changed. In general, the easier the outcome meas-
ure is to assess, the less meaningful it may be. Although it 
is the common standard for ECMO, short-term survival 
to hospital discharge is not a particularly satisfactory 
outcome measure because not only can it not be used 
to assess quality of life in survivors, some studies have 
demonstrated that there is a significant late death rate in 
a number of conditions [38, 39]. More and more studies 
are being conducted examining very late outcomes after 
paediatric ECMO, ranging from median follow-up times 
of 4–15  years, and including a wide range of outcome 
measures such as long-term survival, neurodevelopmen-
tal outcomes and quality of life [38–44]. Several of these 
studies have no parallel in adult ECMO populations or, 
indeed, adult ICU populations and include testing exer-
cise capacity 10–15 years after ECMO [40], 7-year neu-
rocognitive follow-up after an RCT of ECMO [41] and 
8-year nationwide follow-up of every neonatal ECMO 
survivor in a country [42].
Haemolysis causes demonstrable harm
Haemolysis, as reflected by rising plasma haemoglobin, is 
associated with increased mortality in children [45]. Hae-
molysis may be more common in small children because 
of the technical difficulties associated with placing large 
cannulas in small blood vessels. There is sufficient evi-
dence that iatrogenic haemolysis is a contributor to criti-
cal care mortality and every effort should be directed 
towards minimizing it [46]. In adults, persistently high 
plasma haemoglobin has a complex but important asso-
ciation with CRRT requirements, longer ECMO runs and 
higher mortality rates [47, 48].
Complex congenital heart disease and ECMO is 
coming to your adult ICU soon
In many high-income countries, there are now more 
adults alive with congenital heart disease than children, 
including complex cyanotic congenital heart disease [49]. 
Recent data from the Australia and New Zealand Fon-
tan Registry showed that patients who underwent the 
conventional (atriopulmonary) Fontan operation had 
76  % 25-year survival. With more recent modifications 
(lateral tunnel or extracardiac conduit), current 10-year 
survival in these patients is 97  % [50]. These patients 
have undergone multiple operations, require more elab-
orate cannulation strategies to decompress both vena 
cavae and commonly have difficult vascular access and 
complex physiology not often understood by clinicians 
untrained in or unfamiliar with this population. Many 
of them are candidates for extracorporeal support, as a 
bridge to recovery (e.g. following surgery or as a result 
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of concomitant respiratory infection), surgical revision 
(e.g. thrombosis of the conduits) or ventricular assist 
device implantation and transplantation (e.g. irreversible 
myocardial failure due to uncorrectable atrioventricular 
valve regurgitation and chronic volume overload). Early 
cannulation is often necessary because extracorporeal 
cardiopulmonary resuscitation (ECPR) in this patient 
group is associated with extremely poor outcomes, prob-
ably because of the ineffectiveness of conventional CPR 
at providing systemic blood flow while simultaneously 
causing cerebral injury because of impedance to cerebral 
venous drainage. Medium-term goals after cannulation 
may require extensive multidisciplinary collaboration 
because of the need to gather the requisite information 
in order to plan bridging the patient from ECMO to a 
more definitive strategy. Meticulous understanding of 
the Fontan circulation is essential to optimize outcomes. 
However, few countries have prepared adequately for the 
incoming wave of critically ill patients with adult con-
genital heart disease (ACHD) and it is likely that multi-
disciplinary collaboration between adult and paediatric 
clinicians experienced with these conditions offers the 
best hope at present for patient care, until sufficient dedi-
cated ACHD institutions can be established [51].
Conclusions
There are many unanswered questions about the role of 
ECMO in adults and children, but it is clear that, similar 
to mechanical ventilation, no classic RCT will be done. 
It is a therapy that has evolved disease-by-disease and 
patient group-by-patient group. With increasing safety 
and improving technology, it is a therapy that is here to 
stay. Indications will change, and the role of mechanical 
support as an individual therapy and a platform to facili-
tate other therapies is increasing. Paediatric clinicians 
have a long perspective on ECMO, outcome and follow-
up, but adult clinicians are increasingly using ECMO in a 
variety of situations and rapidly developing new clinical 
paradigms of care. Good communication will ensure that 
both groups continue to learn from each other.
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